The role of hypoxia inducible factor-1alpha in gynecological cancer

Laura M S Seeber, Nicole Horrée, Marc A G G Vooijs, A. Peter M Heintz, Elsken van der Wall, René H M Verheijen, Paul J. Van Diest

Research output: Contribution to journalArticle

Abstract

Understanding the mechanisms of carcinogenesis and progression of gynecological tumors is important as these insights might lead to improved diagnostic tools for the pathologist, improved prediction of prognosis, response to therapy, and eventually better biology-based disease management, thereby improving prognosis and quality of life for the individual patient. Hypoxia is an important event in carcinogenesis because it renders a more aggressive phenotype with increased invasiveness and proliferation, formation of metastases and poorer survival. Although selecting patients with hypoxic tumors may therefore be clinically important, there is no consensus as to the method best suited for routine assessment of hypoxia. One of the potential tumor hypoxia markers is hypoxia inducible factor 1 (HIF-1). HIF-1 is the key cellular survival protein under hypoxia, and is associated with tumor progression and metastasis in various solid tumors. In this review, we show that in gynecological cancers, HIF-1A is emerging as an important factor in carcinogenesis, and that overexpression of HIF-1A and its target genes CA9 and SLC2A1 seems associated with shorter progression free- and overall survival. Since hypoxia and HIF-1A expression are associated with treatment failure, targeting HIF-1A could be an attractive therapeutic strategy with the potential for disrupting multiple pathways crucial for tumor growth. Currently, HIF-1A inhibitors are being studied in clinical trials in recurrent ovarian- and cervical cancer, and trials in other gynecological cancers are expected.

Original languageEnglish (US)
Pages (from-to)173-184
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume78
Issue number3
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Neoplasms
Hypoxia-Inducible Factor 1
Carcinogenesis
Neoplasm Metastasis
Survival
Tumor Biomarkers
Disease Management
Hypoxia
Treatment Failure
Uterine Cervical Neoplasms
Ovarian Neoplasms
Disease-Free Survival
Quality of Life
Clinical Trials
Phenotype
Therapeutics
Growth
Genes
Proteins

Keywords

  • Cervical cancer
  • Endometrial cancer
  • Hypoxia
  • Hypoxia inducible factor-1alpha
  • Ovarian cancer
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Seeber, L. M. S., Horrée, N., Vooijs, M. A. G. G., Heintz, A. P. M., van der Wall, E., Verheijen, R. H. M., & Van Diest, P. J. (2011). The role of hypoxia inducible factor-1alpha in gynecological cancer. Critical Reviews in Oncology/Hematology, 78(3), 173-184. https://doi.org/10.1016/j.critrevonc.2010.05.003

The role of hypoxia inducible factor-1alpha in gynecological cancer. / Seeber, Laura M S; Horrée, Nicole; Vooijs, Marc A G G; Heintz, A. Peter M; van der Wall, Elsken; Verheijen, René H M; Van Diest, Paul J.

In: Critical Reviews in Oncology/Hematology, Vol. 78, No. 3, 06.2011, p. 173-184.

Research output: Contribution to journalArticle

Seeber, LMS, Horrée, N, Vooijs, MAGG, Heintz, APM, van der Wall, E, Verheijen, RHM & Van Diest, PJ 2011, 'The role of hypoxia inducible factor-1alpha in gynecological cancer', Critical Reviews in Oncology/Hematology, vol. 78, no. 3, pp. 173-184. https://doi.org/10.1016/j.critrevonc.2010.05.003
Seeber LMS, Horrée N, Vooijs MAGG, Heintz APM, van der Wall E, Verheijen RHM et al. The role of hypoxia inducible factor-1alpha in gynecological cancer. Critical Reviews in Oncology/Hematology. 2011 Jun;78(3):173-184. https://doi.org/10.1016/j.critrevonc.2010.05.003
Seeber, Laura M S ; Horrée, Nicole ; Vooijs, Marc A G G ; Heintz, A. Peter M ; van der Wall, Elsken ; Verheijen, René H M ; Van Diest, Paul J. / The role of hypoxia inducible factor-1alpha in gynecological cancer. In: Critical Reviews in Oncology/Hematology. 2011 ; Vol. 78, No. 3. pp. 173-184.
@article{8dbb0aa2572a44429601be1c9ac7e4eb,
title = "The role of hypoxia inducible factor-1alpha in gynecological cancer",
abstract = "Understanding the mechanisms of carcinogenesis and progression of gynecological tumors is important as these insights might lead to improved diagnostic tools for the pathologist, improved prediction of prognosis, response to therapy, and eventually better biology-based disease management, thereby improving prognosis and quality of life for the individual patient. Hypoxia is an important event in carcinogenesis because it renders a more aggressive phenotype with increased invasiveness and proliferation, formation of metastases and poorer survival. Although selecting patients with hypoxic tumors may therefore be clinically important, there is no consensus as to the method best suited for routine assessment of hypoxia. One of the potential tumor hypoxia markers is hypoxia inducible factor 1 (HIF-1). HIF-1 is the key cellular survival protein under hypoxia, and is associated with tumor progression and metastasis in various solid tumors. In this review, we show that in gynecological cancers, HIF-1A is emerging as an important factor in carcinogenesis, and that overexpression of HIF-1A and its target genes CA9 and SLC2A1 seems associated with shorter progression free- and overall survival. Since hypoxia and HIF-1A expression are associated with treatment failure, targeting HIF-1A could be an attractive therapeutic strategy with the potential for disrupting multiple pathways crucial for tumor growth. Currently, HIF-1A inhibitors are being studied in clinical trials in recurrent ovarian- and cervical cancer, and trials in other gynecological cancers are expected.",
keywords = "Cervical cancer, Endometrial cancer, Hypoxia, Hypoxia inducible factor-1alpha, Ovarian cancer, Prognosis, Therapy",
author = "Seeber, {Laura M S} and Nicole Horr{\'e}e and Vooijs, {Marc A G G} and Heintz, {A. Peter M} and {van der Wall}, Elsken and Verheijen, {Ren{\'e} H M} and {Van Diest}, {Paul J.}",
year = "2011",
month = "6",
doi = "10.1016/j.critrevonc.2010.05.003",
language = "English (US)",
volume = "78",
pages = "173--184",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - The role of hypoxia inducible factor-1alpha in gynecological cancer

AU - Seeber, Laura M S

AU - Horrée, Nicole

AU - Vooijs, Marc A G G

AU - Heintz, A. Peter M

AU - van der Wall, Elsken

AU - Verheijen, René H M

AU - Van Diest, Paul J.

PY - 2011/6

Y1 - 2011/6

N2 - Understanding the mechanisms of carcinogenesis and progression of gynecological tumors is important as these insights might lead to improved diagnostic tools for the pathologist, improved prediction of prognosis, response to therapy, and eventually better biology-based disease management, thereby improving prognosis and quality of life for the individual patient. Hypoxia is an important event in carcinogenesis because it renders a more aggressive phenotype with increased invasiveness and proliferation, formation of metastases and poorer survival. Although selecting patients with hypoxic tumors may therefore be clinically important, there is no consensus as to the method best suited for routine assessment of hypoxia. One of the potential tumor hypoxia markers is hypoxia inducible factor 1 (HIF-1). HIF-1 is the key cellular survival protein under hypoxia, and is associated with tumor progression and metastasis in various solid tumors. In this review, we show that in gynecological cancers, HIF-1A is emerging as an important factor in carcinogenesis, and that overexpression of HIF-1A and its target genes CA9 and SLC2A1 seems associated with shorter progression free- and overall survival. Since hypoxia and HIF-1A expression are associated with treatment failure, targeting HIF-1A could be an attractive therapeutic strategy with the potential for disrupting multiple pathways crucial for tumor growth. Currently, HIF-1A inhibitors are being studied in clinical trials in recurrent ovarian- and cervical cancer, and trials in other gynecological cancers are expected.

AB - Understanding the mechanisms of carcinogenesis and progression of gynecological tumors is important as these insights might lead to improved diagnostic tools for the pathologist, improved prediction of prognosis, response to therapy, and eventually better biology-based disease management, thereby improving prognosis and quality of life for the individual patient. Hypoxia is an important event in carcinogenesis because it renders a more aggressive phenotype with increased invasiveness and proliferation, formation of metastases and poorer survival. Although selecting patients with hypoxic tumors may therefore be clinically important, there is no consensus as to the method best suited for routine assessment of hypoxia. One of the potential tumor hypoxia markers is hypoxia inducible factor 1 (HIF-1). HIF-1 is the key cellular survival protein under hypoxia, and is associated with tumor progression and metastasis in various solid tumors. In this review, we show that in gynecological cancers, HIF-1A is emerging as an important factor in carcinogenesis, and that overexpression of HIF-1A and its target genes CA9 and SLC2A1 seems associated with shorter progression free- and overall survival. Since hypoxia and HIF-1A expression are associated with treatment failure, targeting HIF-1A could be an attractive therapeutic strategy with the potential for disrupting multiple pathways crucial for tumor growth. Currently, HIF-1A inhibitors are being studied in clinical trials in recurrent ovarian- and cervical cancer, and trials in other gynecological cancers are expected.

KW - Cervical cancer

KW - Endometrial cancer

KW - Hypoxia

KW - Hypoxia inducible factor-1alpha

KW - Ovarian cancer

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79955658283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955658283&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2010.05.003

DO - 10.1016/j.critrevonc.2010.05.003

M3 - Article

C2 - 20627616

AN - SCOPUS:79955658283

VL - 78

SP - 173

EP - 184

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -